ContextVision AB
OSE:CONTX

Watchlist Manager
ContextVision AB Logo
ContextVision AB
OSE:CONTX
Watchlist
Price: 3.93 NOK 2.88% Market Closed
Market Cap: 304.1m NOK

ContextVision AB
Investor Relations

ContextVision AB operates as a medical technology software company that specializes in image analysis and artificial intelligence. The company is headquartered in Stockholm, Stockholm and currently employs 53 full-time employees. The firm's products are tailored primarily for medical imaging equipment manufacturers. Its product portfolio is structured into six groups, namely Mammography, comprising such products, as GOPView MAMMO, MAMMO PLUSViev and C-CAD; Ultrasound, comprising the US PlusView family of products, GOPView USXI and GOPiCE US products; Magnetic Resonance Imagining (MRI), comprising the GOPView MRI2 product; Computer tomography (CT), comprising the GOPView CT software; Digital X-Ray, comprising such products, as GOPView XR2 and GOPView XR2-DI, among others, and Interventional Radiology/Fluoroscopy, comprising the GOPView IRV Plus and GOPView IRV Ultra products. As of December 31, 2011, the Company had one wholly owned subsidiary, ContextVision Inc, based in the United States.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Revenue Drop: Q3 revenue fell to SEK 23.7 million, down 21% year-over-year, mainly due to lower license sales and continued market headwinds.

Profitability Hit: Adjusted EBITDA was SEK 4 million with a 16.7% margin, impacted by lower sales, continued R&D investments, and a non-recurring tax expense.

Cash Position: ContextVision maintains a solid cash balance of SEK 67.5 million, despite a negative cash flow in the quarter, supporting ongoing investments and a share buyback program.

Strategic Progress: Key milestones were reached in both image quality (new OEM contracts, upcoming product launch) and data quality (secured clinical study approvals).

Market Challenges: Management attributes the sales decline to broader market uncertainties, price pressure, and delayed procurements, but sees no structural customer loss.

Key Financials
Revenue
SEK 23.7 million
Adjusted EBITDA
SEK 4 million
Adjusted EBITDA Margin
16.7%
Operating Cash Flow (after working capital)
negative SEK 2 million
Total Cash Flow (Q3)
negative SEK 2.9 million
Cash Position
SEK 67.5 million
Revenue (First 9 Months)
SEK 78.6 million
Total Cash Flow (First 9 Months)
negative SEK 6.9 million
Earnings Call Recording
Other Earnings Calls

Management

Dr. Gerald Potzsch
Chief Executive Officer
No Bio Available
Mr. Sven Gunther-Hanssen
Co-Founder & Director
No Bio Available
Mr. Richard Hallstrom
Chief Financial Officer
No Bio Available
Mr. Gunnar Lathen
Chief Technology Officer
No Bio Available
Mr. Ola Lindblad
Chief Sales & Marketing Officer
No Bio Available
Ms. Katarina Flood
Chief Product & Service Officer
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Klara Norra Kyrkogata 31
Contacts